Table 1.
Discovery cohort | Validation cohort | Follow-up cohort (n=8) |
Healthy control (n = 23) |
|||
---|---|---|---|---|---|---|
Characteristics | Non-survivors (n = 15) | Survivors (n = 14) | Non-survivors (n = 30) | Survivors (n = 30) | ||
Mean age in years (range) |
57 (36–81) |
51 (28–74) |
62 | 60 | 50 (32–70) |
43 |
(45–84) | (34–80) | (28–68) | ||||
Male (%) | 11 (73%) | 10 (71%) | 26 (87%) | 21 (70%) | 8 (100%) | 14 (61%) |
Comorbidity | ||||||
Diabetes (%) | 9 (60%) | 7 (50%) | 18 (60%) | 17 (57%) | 7 (88%) | – |
Alcoholism (%) | 3 (20%) | 6 (43%) | 7 (23%) | 10 (33%) | 3 (38%) | – |
Kidney disease (%) | 2 (13%) | 1 (7%) | 5 (17%) | 3 (10%) | 5 (63%) | – |
Hypertension (%) | 5 (33%) | 2 (14%) | 13 (43%) | 7 (23%) | 3 (38%) | – |
Thalassemia (%) | – | 2 (14%) | – | 1 (3%) | – | – |
Cancer (%) | 2 (13%) | – | 2 (7%) | 1 (3%) | – | – |
None (%) | 3 (20%) | 1 (7%) | 4 (13%) | 4 (13%) | – | 23 (100%) |
Clinical symptom | ||||||
Bacteremia (%) | 14 (93%) | 8 (57%) | 28 (93%) | 23 (77%) | 7 (88%) | – |
Fever | ||||||
<15 days (%) | 14 (93%) | 11 (79%) | 28 (93%) | 23 (77%) | 7 (88%) | – |
≥15 days (%) | 1 (7%) | 3 (21%) | 2 (7%) | 7 (23%) | 1 (13%) | – |